Individualized target detection scheme for non-small cell lung cancer
Release time：
Sep 30,2022
source：
Currently, the morbidity and mortality of lung cancer ranks first among all malignant tumors in China. Non-small cell lung cancer patients account for 80-85% of the total number of lung cancer patients, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, its cancer cells grow and divide slowly and spread and metastasize relatively late.
| type of drug | target gene | sample type | |
| targeted drugs | Gefitinib Erlotinib |
EGFR |
Fresh tissue, paraffin-embedded tissue, plasma |
|
K-ras |
Fresh tissue, paraffin-embedded tissue, plasma | ||
|
B-raf |
|||
|
PIK3CA |
|||
| cetuximab panitumumab |
K-ras |
||
|
N-ras |
|||
| Crizotinib |
ALK |
Fresh tissue, paraffin-embedded tissue, plasma | |
|
ROS1 |
|||
|
RET融合 |
|||
| Chemotherapy drugs | Platinum |
ERCC1 |
Fresh tissue, paraffin-embedded tissue |
|
BRCA1 |
|||
|
TP53 |
|||
| Paclitaxel Vinblastine etc. |
STMN1 |
||
|
TUBB3 |
|||
| Fluorine |
TYMS |
||
|
TYMP |
|||
|
DPYD |
|||
| Etoposide |
TOP2A |
||
| Gemcitabine |
RRM1 |
||
| irinotecan |
UGT1A1 |
Whole blood | |
